Your Health, We Care
Release date: 2024-08-22 17:28:49 Recommended: 119
Alpelisib, approved in combination with fulvestrant in 2019 for the treatment of HR/HER2- breast cancer, specifically PIK3CA mutation cases; By inhibiting the PI3K pathway, it can effectively control the proliferation of tumor cells.
Alpelisib is a PIK3CA kinase inhibitor used for the treatment of HR/HER2- advanced breast cancer, particularly in those patients with PIK3CA mutations. It is used in combination with fulvestrant to inhibit the proliferation of tumor cells by blocking the PI3K pathway.
The drug was approved by the FDA in 2019 and offers a new treatment option for breast cancer patients. It is effective in controlling tumors that are resistant to traditional treatments. The use of apellix in special populations requires special attention to the dosage and appropriate adjustment of the treatment regimen.
The use of Alpelisib in special populations needs to be adjusted on an individual basis.
Animal studies have shown that Alpelisib is potentially harmful to the fetus, including embryonic death, weight loss, and malformations. There are currently insufficient data on specific risks for pregnant women. Pregnant women should avoid this medicine.
There is a lack of data on the presence of apellix in breast milk. Breastfeeding women are advised to stop breastfeeding during the medication and for a week after the last dose.
After understanding the medication precautions for these special populations, the next step is to focus on the indications of Alpelisib to better understand the therapeutic scope of the drug.
Alpelisib is used in combination with fulvestrant for the treatment of specific types of breast cancer, and the specific indications are described in detail below.
HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer that has progressed after endocrine-based therapy.
HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer that continues to progresse after endocrine therapy.
The combination of apelis and fulvestrant offers a new treatment option for patients with these specific types of breast cancer. Understanding the drug indications can better guide the clinical treatment plan.
[Warm tips] When using Alpelisib, you should follow your doctor's guidance and monitor your condition and drug reactions regularly. When used in special populations, pay attention to adjusting the treatment plan; If you have any concerns or discomfort, consult your doctor promptly.
